์ ๋งฅ์ฃผ์ฌ์ฉ ์ง๋ฐฉ์ ์
**์ ๋งฅ์ฃผ์ฌ์ฉ ์ง๋ฐฉ์ ์ (IFE/ILE)**๋ ์ ๋งฅ ํฌ์ฌ๋ฅผ ์ํด ์ค๋น๋ ๋ฌด๊ท , ๋ฌด๋ฐ์ด์ฑ ์ง๋ฐฉ ์ ์ ์ ๋๋ค. ์ญ์ฌ์ ์ผ๋ก ์ฃผ๋ก **๋น๊ฒฝ๊ตฌ ์นผ๋ก๋ฆฌ ๋ฐ ํ์ ์ง๋ฐฉ์ฐ ๊ณต๊ธ์**์ผ๋ก ์ฌ์ฉ๋์์ผ๋, ์ต๊ทผ ์์ ๋ ์ฑํ์์ ์ค์ํ **์๊ธ ํด๋ ์ **๋ก ๋ถ์ํ์ต๋๋ค. ๊ธฐ์กด ์น๋ฃ๋ฒ์ด ์คํจํ์ ๋ ๊ณ ์ง์ฉ์ฑ ์ฝ๋ฌผ๋ก ์ธํ ์๋ช ์ํ์ ์ธ ๋ ์ฑ์ ์น๋ฃํ๋ ๋ฐ ๋งค์ฐ ํจ๊ณผ์ ์ ๋๋ค. **์ฃผ์ ์์ ์ ์ฉ:** * **๋ ์ฑํ ์๊ธ ์ฒ์น:** ๊ตญ์ ๋ง์ทจ์ (๋ถํผ๋ฐ์นด์ธ, ๋ฆฌ๋์นด์ธ), ๋ํฌ๋ก๋ผ์ด๋๊ณ(์ด๋ฒ๋ฉํด, ๋ชฉ์๋ฑํด), ์นผ์ ์ฑ๋ ์ฐจ๋จ์ (์๋ก๋ํ), ๋ฒ ํ ์ฐจ๋จ์ ๋ฐ ํน์ ํญ์ฐ์ธ์ /ํญ์ ์ ๋ณ ์ฝ๋ฌผ. * **๋น๊ฒฝ๊ตฌ ์์(PN):** ๊ณ ๋ฐ๋ ์นผ๋ก๋ฆฌ๋ฅผ ์ ๊ณตํฉ๋๋ค(20% ์ฉ์ก์ ๊ฒฝ์ฐ ์ฝ 2 kCal/mL). *์ฐธ๊ณ : ์ ์ฌ์ ์ธ ๋ฉด์ญ ์ต์ ๋ฐ ๊ฐ์ผ ์ํ ๋๋ฌธ์ ์ค์ฆ ํ์์ ์์ ๊ณต๊ธ์ ์ํ ์ฌ์ฉ์ ๋ ผ๋์ ์ฌ์ง๊ฐ ์์ต๋๋ค.*
์์ฉ ๊ธฐ์ : **Toxicologic Mechanism (Antidote):** * **"Lipid Sink" Theory:** IFE creates an expanded intravascular lipid phase. Highly lipophilic toxins partition out of target tissues (e.g., myocardium, CNS) and into this "lipid sink" within the plasma, reducing the free (active) drug concentration at receptor sites. * **Metabolic/Cardiac Enhancement:** Provides a direct energy substrate (free fatty acids) to the myocardium, overcoming mitochondrial lipid metabolism blockade (e.g., by bupivacaine) and increasing intracellular calcium to improve cardiac contractility. **Nutritional Mechanism:** * Provides a dense source of calories and essential fatty acids (linoleic, linolenic acids) necessary for cellular integrity and metabolism.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Parenteral Nutrition (PN) ยท 25-60% of calories administered. Traditionally not recommended at > 2 g/kg/day for TPN therapy. ยท IV ยท CRI ยท As needed ยท Consult a veterinary nutritionist.
- Rescue agent for fat-soluble drug/toxin intoxication ยท IFE 20% via a sterile, peripheral IV catheter as a 1.5 mL/kg bolus over 1-3 minutes, then 0.25-0.5 mL/kg/min for 30-60 min. The bolus could be repeated in case of cardiac arrest. If symptomatic after traditional dosing, consider additional doses of 1.5 mL/kg IV over 30 min q4-6h for 24-36 hours until clinical signs resolve, or maintaining a CRI of 0.5 mL/kg/hour until clinical signs resolve. ยท IV ยท Bolus followed by CRI ยท Until clinical signs resolve ยท Extrapolated from general veterinary/human guidelines.
- Parenteral Nutrition (PN) ยท 25-60% of calories administered. Traditionally not recommended at > 2 g/kg/day for TPN therapy. ยท IV ยท CRI ยท As needed ยท Consult a veterinary nutritionist. Keep PPN solutions below 600 mOsm/L.
- Rescue agent for fat-soluble drug/toxin intoxication ยท IFE 20% via a sterile, peripheral IV catheter as a 1.5 mL/kg bolus over 1-3 minutes, then 0.25-0.5 mL/kg/min for 30-60 min. The bolus could be repeated in case of cardiac arrest. If symptomatic after traditional dosing, consider additional doses of 1.5 mL/kg IV over 30 min q4-6h for 24-36 hours until clinical signs resolve, or maintaining a CRI of 0.5 mL/kg/hour until clinical signs resolve. ยท IV ยท Bolus followed by CRI ยท Until clinical signs resolve ยท Do not exceed 8 mL/kg/day generally, though this has been exceeded in acute toxicosis without ill effect.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Severe egg yolk allergies
- Abnormal fat metabolism
- Premature and low-birth weight infants (human black box warning)
- Blood coagulation disorders
- Pulmonary disease
- Renal impairment
- Severe liver damage
- Patients at high risk for fat emboli
์ด์๋ฐ์
- Sepsis or thrombophlebitis (secondary to IV catheterization)
- Fat overload syndrome (hyperlipidemia, hepatomegaly, icterus, splenomegaly, fat embolism, thrombocytopenia, hemolysis, prolonged clotting times)
- Pulmonary toxicity (temporary)
- GI effects
- Somnolence
- Headache
- Flushing
- Pancreatitis
- Hypercoagulability
- Hypersensitivity
์ฝ๋ฌผ ์ํธ์์ฉ
- Lipid Soluble Drugs ยท IFE may act as a 'lipid sink', reducing the free circulating levels and clinical efficacy of concurrently administered lipophilic medications.
๋ชจ๋ํฐ๋ง
- Serum/plasma drug levels (for toxicology tracking)
- Blood glucose
- Serum triglycerides and gross lipemia
- PCV and Total Protein
- IV catheter site status (phlebitis/sepsis)
- Hydration status and vital signs (temp, HR, RR)
- Serum electrolytes (including phosphorus)
- Renal and liver function tests
- CBC
- Coagulation times (if using heparin)
๊ณผ์ฉ๋
In the event of inadvertent overdose or severe fat overload, **stop the infusion** until the lipid has cleared from the plasma. Clearance can be evaluated visually (inspecting hematocrit tubes for lipemia) or via laboratory methods (triglyceride concentrations, nephelometry). If severe hyperlipidemia occurs during toxicity treatment, **heparin therapy (75-250 Units/kg SQ q6h)** may be considered to increase lipid clearance via lipoprotein lipase activation. However, weigh risks carefully, as heparin may alter the antidote mechanism. Monitor PTT; if PTT exceeds 2-2.5X normal, lower heparin dose (75 Units/kg SQ q6-8h) or discontinue.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.